
Opinion|Videos|October 21, 2024
Health Care Resource Utilization: Luspatercept vs ESAs in MDS
Author(s)Saeed Sadeghi, MD
Saeed Sadeghi, MD, discusses the impact of health care resource utilization on treatment decisions and quality of life for patients with myelodysplastic syndromes (MDS), highlighting real-world data presented at SOHO that compares the resource utilization of U.S. patients treated with luspatercept versus erythropoiesis-stimulating agents (ESAs).
Advertisement
Episodes in this series

Video content above is prompted by the following:
Health care resource utilization is an important factor in deciding on treatments and affects quality of life for patients.
- Please briefly discuss the real-world data presented at SOHO comparing the health resource utilization of US patients with MDS treated with luspatercept vs ESAs.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
5






























